Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/60586
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOlarn Arpornchayanonen_US
dc.contributor.authorTaninnit Leerapunen_US
dc.date.accessioned2018-09-10T03:45:46Z-
dc.date.available2018-09-10T03:45:46Z-
dc.date.issued2008-10-01en_US
dc.identifier.issn01252208en_US
dc.identifier.issn01252208en_US
dc.identifier.other2-s2.0-55249104076en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=55249104076&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/60586-
dc.description.abstractGiant cell tumor is a benign locally aggressive tumor. The standard treatment is en bloc resection followed by major reconstructive surgery, or extended curettage conjunction with bone grafting or the use of bone cement implantations. Surgical treatment of giant cell tumor at the sacrum is associated with high morbidity, and local recurrence. The authors present a case of giant cell tumor at the sacrum treated with intravenous 4 mg zoledronate every 4 weeks for seven courses followed with curettage and cement implantation. At two years follow-up, the patient had no pain, no neurological deficit, and no local recurrence. The patient's gait was normal. From the present study, the authors demonstrate the effectiveness of zoledronate for treatment of giant cell tumor at the sacrum. It can reduce the morbidity from major surgery.en_US
dc.subjectMedicineen_US
dc.titleEffectiveness of intravenous bisphosphonate in treatment of giant cell tumor: A case report and review of the literatureen_US
dc.typeJournalen_US
article.title.sourcetitleJournal of the Medical Association of Thailanden_US
article.volume91en_US
article.stream.affiliationsChiang Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.